Profound Medical Corp. (TSE:PRN) Director Arun Menawat Dr. Purchases 14,200 Shares

Profound Medical Corp. (TSE:PRN) Director Arun Menawat Dr. purchased 14,200 shares of the company’s stock in a transaction on Friday, March 14th. The shares were bought at an average price of C$10.09 per share, with a total value of C$143,319.75.

Profound Medical Trading Up 0.1 %

TSE PRN opened at C$9.67 on Wednesday. Profound Medical Corp. has a one year low of C$7.90 and a one year high of C$15.75. The firm has a 50 day simple moving average of C$9.89 and a 200-day simple moving average of C$10.50. The firm has a market cap of C$203.77 million, a price-to-earnings ratio of -5.02 and a beta of 0.81. The company has a debt-to-equity ratio of 20.05, a quick ratio of 14.98 and a current ratio of 6.12.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.